PTC Therapeutics Inc (PTCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) has a cash flow conversion efficiency ratio of 0.327x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.04 Million) by net assets ($-180.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PTC Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
PTC Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how PTC Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PTC Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PTC Therapeutics Inc ranked by their cash flow conversion efficiency. Explore PTC Therapeutics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gland Pharma Limited
NSE:GLAND
|
0.057x |
|
United Plantations Bhd
KLSE:2089
|
0.337x |
|
Balchem Corporation
NASDAQ:BCPC
|
0.031x |
|
Swatch Group AG Class N
SW:UHRN
|
0.026x |
|
Almonty Industries Inc
AU:AII
|
-0.035x |
|
Flagstar Financial, Inc.
NYSE:FLG
|
-0.016x |
|
TEMENOS AG UNSP.ADR/1
F:TE8A
|
0.282x |
|
TDG Holding Co Ltd
SHG:600330
|
0.001x |
Annual Cash Flow Conversion Efficiency for PTC Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of PTC Therapeutics Inc from 2011 to 2025. View PTC Therapeutics Inc (PTCT) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-205.31 Million | $711.20 Million | -3.464x | -3632.12% |
| 2024-12-31 | $-1.10 Billion | $-107.69 Million | 0.098x | -49.33% |
| 2023-12-31 | $-818.55 Million | $-158.42 Million | 0.194x | -81.17% |
| 2022-12-31 | $-347.09 Million | $-356.65 Million | 1.028x | +100.59% |
| 2021-12-31 | $1.44 Million | $-251.33 Million | -174.779x | -43306.93% |
| 2020-12-31 | $481.98 Million | $-194.07 Million | -0.403x | -142.61% |
| 2019-12-31 | $594.33 Million | $-98.64 Million | -0.166x | -110.59% |
| 2018-12-31 | $350.73 Million | $-27.64 Million | -0.079x | -22.52% |
| 2017-12-31 | $156.44 Million | $-10.06 Million | -0.064x | +92.57% |
| 2016-12-31 | $119.58 Million | $-103.57 Million | -0.866x | -107.89% |
| 2015-12-31 | $298.47 Million | $-124.34 Million | -0.417x | -117.09% |
| 2014-12-31 | $298.47 Million | $-57.27 Million | -0.192x | +44.16% |
| 2013-12-31 | $136.54 Million | $-46.92 Million | -0.344x | -113.76% |
| 2012-12-31 | $-19.19 Million | $-47.93 Million | 2.497x | +2768.93% |
| 2011-12-31 | $-238.60 Million | $-20.77 Million | 0.087x | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more